ArticleMolecular therapy. Nucleic acids2020
Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma.
Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 205 citations in OpenAlex.
- A 4-cuproptosis-related lncRNA theragnostic signature predicts survival and immunotherapy response in patients with lung adenocarcinoma.Molecular and clinical oncology · 2026Article
- Immune-related long noncoding RNAs in predicting the prognosis and immune landscape of intrahepatic cholangiocarcinoma: a bioinformatics analysis with experimental verification.Translational cancer research · 2025Article
- Clinical value of multiparameters of 2-[ 18 F]-fluoro-2-deoxy-glucose PET/MRI in tumor/lymph node staging of esophageal squamous cell carcinoma.Nuclear medicine communications · 2025Article
- Dual-Function RNA Biomarkers: Integrating Relapse Prediction and Immune Profiling in Triple-Negative Breast Cancer.International journal of medical sciences · 2025Article
- Construction and validation of a necroptosis-related lncRNA signature for predicting the prognosis of gastrointestinal cancer patients.Frontiers in immunology · 2025Article
- Enhanced prognostic and immunomodulatory effects of novel cuproptosis-related long noncoding RNAs in wilms tumor.Frontiers in molecular biosciences · 2025Article
- A Pyroptosis-Related LncRNA Signature for Predicting Prognosis, Immune Features and Drug Sensitivity in Ovarian Cancer.OncoTargets and therapy · 2025Article
- Identification of an Anoikis-associated LncRNA Signature to Predict the Clinical Prognosis and Immune Function of Patients with Endometrial Cancer.International journal of medical sciences · 2025Article
- Cell Cycle-Related LncRNA-Based Prognostic Model for Hepatocellular Carcinoma: Integrating Immune Microenvironment and Treatment Response.Current medical science · 2024Article
- Novel signature of ferroptosis-related long non-coding RNA to predict lower-grade glioma overall survival.Discover oncology · 2024Article
- Molecular Mechanisms and Clinical Implications of Noncoding RNAs in Cancer.Non-coding RNA · 2024Article
- Identification of necroptosis-related gene signatures for predicting the prognosis of ovarian cancer.Scientific reports · 2024Article
- Enhancing mHeliyon · 2024Article
- A novel immune-related long noncoding RNA (lncRNA) pair model to predict the prognosis of triple-negative breast cancer.Translational cancer research · 2024Article
- A pyroptosis-related lncRNA-based prognostic index for hepatocellular carcinoma by relative expression orderings.Translational cancer research · 2024Article
- A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC.Aging · 2024Article
- Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.BMC cancer · 2024Article
- Construction and validation of immune-associated lncRNA model for predicting immune status and therapeutic reactions of triple-negative breast cancer.American journal of translational research · 2024Article
- Effects of NK cell-related lncRNA on the immune microenvironment and molecular subtyping for pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Article
- m6A-related lncRNAs as potential biomarkers and the lncRNA ELFN1-AS1/miR-182-5p/BCL-2 regulatory axis in diffuse large B-cell lymphoma.Journal of cellular and molecular medicine · 2024Article
86 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The signature composed of immune-related long noncoding ribonucleic acids (irlncRNAs) with no requirement of specific expression level seems to be valuable in predicting the survival of patients with hepatocellular carcinoma (HCC). Here, we retrieved raw transcriptome data from The Cancer Genome Atlas (TCGA), identified irlncRNAs by co-expression analysis, and recognized differently expressed irlncRNA (DEirlncRNA) pairs using univariate analysis. In addition, we modified Lasso penalized regression. Then, we compared the areas under curve, counted the Akaike information criterion (AIC) values of 5-year receiver operating characteristic curve, and identified the cut-off point to set up an optimal model for distinguishing the high- or low-disease-risk groups among patients with HCC. We then reevaluated them from the viewpoints of survival, clinic-pathological characteristics, tumor-infiltrating immune cells, chemotherapeutics efficacy, and immunosuppressed biomarkers. 36 DEirlncRNA pairs were identified, 12 of which were included in a Cox regression model. After regrouping the patients by the cut-off point, we could more effectively differentiate between them based on unfavorable survival outcome, aggressive clinic-pathological characteristics, specific tumor immune infiltration status, low chemotherapeutics sensitivity, and highly expressed immunosuppressed biomarkers. The signature established by paring irlncRNA regardless of expression levels showed a promising clinical prediction value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.